Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danoprevir/ritonavir plus pegylated interferon and ribavirin after DAA failure in genotype 1 chronic hepatitis C
ChiCTR1800019812Phase 4Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Dec 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of danoprevir, ritonavir, pegylated interferon alpha and ribavirin in hepatitis C virus infection, sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoint: Sustained virologic response at 12 weeks after treatment cessation. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
danoprevirritonavirpegylated interferon alpharibavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on ChiCTR1800019812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019812.